Cite
HARVARD Citation
Chang, L. et al. (2023). Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE). Neurogastroenterology & motility. 35 (5), p. n/a. [Online].